NSE: METROPOLIS | BSE: 542650

Momentum Trap

Download real time

1931.00 -3.10 (-0.16%)

46.84% Gain from 52W Low

9,542 NSE+BSE Volume

NSE 28 Nov, 2025 3:31 PM (IST)

10,006.8

Market Cap

High in industry

Beta 1Year

Very Low volatility

Metropolis Healthcare Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for METROPOLIS, BSE:542650 Metropolis Healthcare Ltd.

Metropolis Healthcare Ltd.

13 Sep 2021

1931.00

-0.16%

Metropolis Healthcare Ltd | Company Update

Buy: Metropolis Healthcare Ltd.

Target

Edelweiss

Healthy expansion plan; major beneficiary of sector consolidation

Metropolis Healthcare Ltd. is trading above its 200 day SMA of 1844.7

Metropolis Healthcare Ltd.

29 May 2021, 12:00AM

1931.00

-0.16%

Metropolis Healthcare Ltd | Q4FY21 Result Update

Buy: Metropolis Healthcare Ltd.

Target

Edelweiss

Strong performance led by core business; Maintain BUY

Metropolis Healthcare Ltd. is trading above its 200 day SMA of 1844.7

Metropolis Healthcare Ltd.

11 Feb 2021

1931.00

-0.16%

Metropolis Healthcare Ltd | Q3FY21 Result Update

Buy: Metropolis Healthcare Ltd.

Target

Edelweiss

Metropolis Healthcare (METROHL) reported yet another strong quarter on continued elevated margins and healthy growth in number of patients.

Metropolis Healthcare Ltd. is trading below its 30 day SMA of 1954.0

Metropolis Healthcare Ltd.

18 Jan 2021

1931.00

-0.16%

Metropolis Healthcare Ltd | Acquisition Update

Buy: Metropolis Healthcare Ltd.

Target

Edelweiss

Metropolis Healthcare (METROHL) has acquired Dr. Ganesan's Hitech Diagnostic Centre (100% stake) for a consideration of INR618cr (combination of cash and stock deal).

Metropolis Healthcare Ltd. is trading below its 30 day SMA of 1954.0

Metropolis Healthcare Ltd.

12 Nov 2020

1931.00

-0.16%

Metropolis Healthcare Ltd - Result Update Q2FY21

Buy: Metropolis Healthcare Ltd.

Target

Edelweiss

Metropolis Healthcare (METROHL) reported strong Q2FY21 results (Revenue/EBITDA/PAT beats estimate by 3%/12%/11.5%).

Metropolis Healthcare Ltd. is trading above its 200 day SMA of 1844.7

Metropolis Healthcare Ltd.

12 Aug 2020

1931.00

-0.16%

Long Term Recommendation | Metropolis Healthcare Ltd

Buy: Metropolis Healthcare Ltd.

Edelweiss

Metropolis Healthcare (METROHL) is one of the largest diagnostic chains in western India, with the region accounting for over 50% of total sales.

Metropolis Healthcare Ltd. is trading below its 30 day SMA of 1954.0

Metropolis Healthcare Ltd.

01 Jun 2020

1931.00

-0.16%

Q4FY20 Result Update - Premium players at risk - Not Rated

Not Rated: Metropolis Healthcare Ltd.

Prabhudas Lilladhar

EBITDA loss was reported for April (CY20) We believe METROHL and other organized players that offers tests at premium pricing to be at risk after the lifting of lockdown due to 1) low footfalls triggering revenue loss 2) high operating cost (for COVID compliance) leading to decline in EBITDA/EBITDA margin 3) expected change in spending pattern of consumers (due to challenging demand scenarios) and 4) competitive pricing pressures to maintain market share. These factors may lead to customer preference towards low-cost local and unorganized players....

Metropolis Healthcare Ltd. is trading above its 200 day SMA of 1844.7

Metropolis Healthcare Ltd.

02 Mar 2020

1931.00

-0.16%

Ashika - Stock Picks - Metropolis Healthcare Ltd. - March 2020

Buy: Metropolis Healthcare Ltd.

Ashika Research

plenty of room for growth of organized players since 80% of the market is catered by un-organized players. Favorable government incentives like tax breaks towards preventive testing could further add to volume growth. Besides, organized players could easily pass on price hikes of ~0.5% p.a to cover medical cost inflation...

Metropolis Healthcar.. has an average target of 2114.50 from 4 brokers.

Metropolis Healthcare Ltd.

20 Jan 2020

1931.00

-0.16%

Management Meet Update

Sell: Metropolis Healthcare Ltd.

Prabhudas Lilladhar

Expansion plan to be led by mix of organic and acquisition route We met the management team of Metropolis Healthcare (METROHL) at their Global Reference(Mumbai) to understand their business outlook for next few fiscals. We believe METROHL will continue to focus on specialized test (low volume and high complexity), and increase its share in B2C business by partnering with local labs (with sizeable track record) and converting them into Metropolis-branded PSCs (Patient Service Centre). Its wide range of test menu and patient shift towards organized diagnostic player are some...

Metropolis Healthcar.. has an average target of 2114.50 from 4 brokers.

Metropolis Healthcare Ltd.

16 Apr 2019

1931.00

-0.16%

METROPOLIS HEALTHCARE LIMITED

Not Rated: Metropolis Healthcare Ltd.

Geojit BNP Paribas

Metropolis Healthcare Ltd (MHL) is one of the leading diagnostics companies having prominence in West and South India. The company offers a comprehensive range of clinical laboratory tests & profiles, and support services to clinical research organizations. MHL operates through laboratory and service network and has implemented a hub and spoke' model for quick and efficient delivery of services. Revenue, EBITDA and PAT grew at a CAGR of 12%, 13% and 22% respectively during FY15-FY18 while the company has maintained an average RoE...

Metropolis Healthcar.. has an average target of 2114.50 from 4 brokers.

VOTE: Is Metropolis Healthcare Ltd. worth buying?

61 Votes:

Buy 80.33%

Sell 9.84%

Hold 9.84%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf